powerpoint presentation on virus

Home PowerPoint Templates PowerPoint Templates Virus Infographics Presentation Template

Virus Infographics Presentation Template

The Virus Infographics Presentation Template features graphics to boost healthcare presentations about infectious diseases. This is a 7 slides PowerPoint deck containing various layout designs to showcase virus-related information. Viruses are parasites that replicate inside living cells at the microscopic level. As the coronavirus pandemic spreads around the world, the discussion around viruses has become a focus point. You can take advantage of the virus infographics template for an overview of microbiological research findings, virus symptoms, prevention, and cure. It is a ready-to-use presentation dedicated to talking about viruses with the help of modern infographics. These infographics include vector-based virus shapes, medical equipment, and prevention options.

The virus infographic theme presents diagrams are available as timelines, core concept, and segmented layout. You can easily replace the text and customize the design of icons to discuss health concerns about viruses. Such as definition of a virus, comparing structure of viruses, discover differences or similarities, historical data, etc. The PowerPoint shapes will help you place everything in context at a glance. For example, use lung infographics to explain how virus attacks and damages lungs. The process diagram is an activity flow that could be used for prevention strategies or recovery afterward. The hand hygiene infographics slide could serve the discussion about effective prevention methods to curb the spread of viruses.

Since influenza, SARS, and COVID-19 continue to emerge and spread across the world. The research on infectious viruses and bacteria has become more valuable. This Virus Infographics Presentation Template will help you create presentation about infectious viruses. The virus slides can be used in several ways to demonstrate different viruses. You can customize the color theme and design of PowerPoint shapes for your minimalist representation of viruses.

You must be logged in to download this file.

Favorite Add to Collection

Details (7 slides)

Supported Versions:

Subscribe today and get immediate access to download our PowerPoint templates.

Related PowerPoint Templates

5-Level Swiss Cheese Model PowerPoint Template

Incident Report PowerPoint Template

Diabetes Presentation Template

Care Pathway Patient Journey Map Template for PowerPoint

Researched by Consultants from Top-Tier Management Companies

Powerpoint Templates

Icon Bundle

Kpi Dashboard

Professional

Business Plans

Swot Analysis

Gantt Chart

Business Proposal

Marketing Plan

Project Management

Business Case

Business Model

Cyber Security

Business PPT

Digital Marketing

Digital Transformation

Human Resources

Product Management

Artificial Intelligence

Company Profile

Acknowledgement PPT

PPT Presentation

Reports Brochures

One Page Pitch

Interview PPT

All Categories

Top 25 Virus PowerPoint Templates To Beat the Invisible Threat

Gunjan Gupta

Viruses are curious little creatures. These tiny tagalongs aren’t exactly living per se, but they are not inanimate either. They’ve replicated themselves into multiple forms both fatal and non-fatal in billions of years and continue to do so even today. These beings have a long trail of history attached to their evolution and perhaps even had a hand or a squishy-squashy protein coating- in helping them mutate and become ever so dangerous. So, much so that they have become a threat to human existence.

In the recent turn of events, where the global pandemic Corona virus popularly known as Covid-19 is on a rise bringing along a chain of untimely deaths and mourns throughout the world, it is necessary to have a much closer look at these tiny microbial compounds. 

If you are also curious to know about these tiny, yet not-so-tiny beings, their origination, evolution, health effects, and more, well tag along.

The evolutionary history of viruses is a fascinating, yet debatable topic for virologists and cell biologists, because of their diverse nature. As such it is a constant struggle to classify these entities and relate their existence to the human tree of life. They may be genetic elements or previously living organisms evolving as parasites. Constant research is going on these topics. 

So, to support the vision of virologists and help them with their never-ending search, SlideTeam professionals have designed a few virus PowerPoint templates that will resolve some of the basic queries about these “microbes”. Each of these templates are apt to unfold new facts about viruses, and their existence, endangering the lives of the only living species in the world- us HUMANS!

Virus Templates to Download and Use 

We are well aware that viruses are diverse in nature and so is their biological composition. Some have RNA genomes while some are made up of DNA genomes. This template can be used to explain the structure as well as the replication strategies of these microbes. It can also be used to explain the dizzying array of functions and health effects of viruses on human health as well as the research conducted on it. Some interesting facts about coronavirus and its genetic mutation can be unfolded in this section and presented to get a better understanding of the origin of this virus. These may include the 10-time mutation study of the virus, posing the biggest threat to humanity. Let alone, various other studies and scientific evidence can be presented by healthcare professionals by utilizing this interesting layout that can be customized. 

  Template 2

Science is the be-all and end-all of our findings. With the outbreak of the world deadliest virus ‘Coronavirus’, creating havoc in the lives of billions of people, this is a classic template that can be used by researchers and scientists to present their interesting studies. The biological composition of various viruses and their origination can be outlined and presented. This template can also be used by healthcare professionals to explain some of the symptoms and ill effects of various viruses. Not all the viruses are deadliest and so information about its various types can be elaborated on in this template. It also comes in handy for biological students to present their research findings after careful analysis of viruses, thus helping them impress their teachers. 

Download Virus Science PowerPoint Templates 

The Internet is flooded with false information about coronavirus and its outbreak. This template can be used by healthcare professionals to create awareness and stop the spreading of false rumors. It can also be used to present the recent worldwide stats of the infection as well as some safety measures that can be adopted by the masses to keep the spread in check. The science behind various viruses can be outlined in this template, to increase the overall understanding of the viewers. Nonetheless, it is an apt design for biomedical students to present their results, findings, and reviews on various viruses to advise medical practitioners. 

Download Virus Science PowerPoint Templates And PowerPoint Background

Influenza is a major public health concern as it infects nearly 5-10% of the global population annually. Hence, there is a need to understand the molecular structure of this virus to reduce its strain on human health. Our professionally designed template can help you give a brief about how the virus multiples, infects, and how to combat infection, making it extremely useful for virologists and cell biologists. Additionally, it can be used to present researchers on few vaccines formulated to reduce the risk of influenza as well as the treatment prescribed. This design is fully adaptive to your needs so feel free to make any changes as you like depending upon your field of interest. 

Download Structure Of The Influenza Virion Medical Images For PowerPoint

This template is ideal for a biology class to show and share important information on various viruses, their origin, infections caused by them, and others. The theme is formal and hence can be used to demonstrate any topic in science class and submit an assignment as well. Doctors, nurses and paramedical staff can also utilize this template to present the information on vaccine reactions which may happen to patients, thus creating awareness. A lot of studies conducted on viruses is also the topic this slide caters to. Additionally, such medical templates are apt for drug health lessons in ordinary schools, colleges, and medical universities. All of these characteristics make this a universally efficient template. Hence, any individual can download it to present his topic in a comprehensive manner. 

Download Virus Microorganism Geographical PowerPoint Templates And PowerPoint Backgrounds

The outbreak of coronavirus throughout the world has become one of the most notorious events of the decade, if not the current century. We can say that we have welcomed a new decade with a catastrophe of death and mourning. Since, this pandemic is nothing short of deadly, taking away lakhs of lives, every bit of information helps a lot. This virus danger template can help you create awareness on this global pandemic. It is a virus and microorganisms based theme template to put everything topic related to the context. The control and prevention of this disease can be the pillars of your talking points after utilizing this presentation theme. Also, there is a consistency in the theme of this template and includes font size that can be easily viewed from a distance. Thus, making it an efficient design that can help you present great presentations on science, biology, virology, and other related fields. 

Download Virus Danger Globe PowerPoint Templates And PowerPoint Backgrounds

This template is designed for HIV and Aids doctors, students, academicians, and other professionals looking for comprehensive designs to create presentations for their universities, hospitals, seminars, and several others. HIV and Aids is a very important topic for medical practitioners to get acquainted with. This template can help you showcase important information on Aids and the causes of its spread. This is also a great design for medics and professionals to convey their thoughts on the topic, thus helping them become better communicators. 

HIV Virus Medical PowerPoint Templates And PowerPoint Backgrounds

The mechanism of HIV entry to the host cell can be explained with this pre-designed template. This layout focuses on the design needs of medical professionals to give a descriptive view of the topic. It is apt for doctors, nurses, paramedics, researchers, academicians, and others working in the field of HIV Aids and its transmission. This content-ready template enables you to deliver great presentations revolving around the topic of HIV with minimum effort and maximum effect. Its simple to download layout requires only a few clicks to get you ready for your upcoming medical presentations. Hence, convey your thoughts and ideas on HIV with this template, that is subjected to numerous alterations, depending upon the requirements of the user. 

Download HIV Attachment To Target T Cell Medical Images For PowerPoint

Classification and explanation of the nomenclature of viruses is a breeze with this template. It is specifically designed for paramedical staff to discuss their views on Hepatitis B and how it affects the liver of the infected patient. Since almost 1 million people die every year because of chronic hepatitis B infection which is preventable and treatable this template comes in very handy to present the important details and facts. Also, new perspectives on the life cycle of hepatitis B can be thoroughly explained in medical universities with this thoughtfully designed template. Since this template is versatile and flexible it is easily adaptable to all your needs and requirements. All you have to do is click on the download button and use it extensively. 

Download Hepatitis B Virus Medical Images For PowerPoint

Template 10

This template can be used to explain the microscopic view and nomenclature of the Papillomavirus or HPV infection. It can also be used to understand its preventive measures, causes, and treatment making it an ideal fit for doctors to give a deeper understanding of the topic. Hospitals and medical universities can utilize this template to teach and train students and staff members. This slide acts as a very good teaching tool as the viewers are able to get a thorough understanding of health care issues, proposed safety measures, reasons for infections, and similar other topics. Additionally, the pre-designed layout of this template showing the entire structure of the virus makes it extremely easy to deliver great medical presentations with minimum effort. 

Download Human Papilloma Virus Medical Images For PowerPoint

Template 11

This template can be used by doctors, medical universities, researchers, virologists, cell biologists, and others to present a thorough understanding of the structure of HIV and how it leads to a non-treatable infection. It showcases two types of infection latent and active and how the synthesis happens. Since this template is so descriptive designed using apt color scheme, it is efficient enough to grab this immediate attention of the viewer. You can either use this template in conjunction with your presentation or as a single entity as it is complete in itself. 

Download Latent And Active Infection Of T Cell By HIV Medical Images For PowerPoint

Template 12

Adenovirus is ubiquitous viruses that cause various pediatric illnesses including common cold. They can also cause gastrointestinal, ophthalmologic, neurologic, and genitourinary symptoms. This template has especially been designed for paramedics and cell biologists to explain the basic structure of adenovirus and its prevention. While illness caused due to viruses have become quite common, having a thorough understanding of the illness is important. This template can be used in a discussion session needing to study the causes of viral growth, its production, and other aspects. Due to its attractive layout, it never fails to impress any audience. 

Download Adenovirus Morphology Medical Images For PowerPoint

Template 13

This is yet another adenovirus template that is suitable to discuss the structure and movement of viruses in the human body. You can also explain the causes of its growth, infection and expansion with this template that is fully adaptable to one’s needs and requirements. Biological experiments and genetic engineering projects can also be presented using this template that is fully responsive. 

Download Adenovirus Medical Images For PowerPoint

Template 14

Download this Leukemia template for your upcoming medical presentations. This template is specifically designed keeping in mind the needs of medical practitioners, healthcare professionals, and pathologists. So, you can easily edit it with your own content as this template uses royalty-free images. Apart from this, the template design can be used as a background of your presentation on leukemia, symptoms, causes, types, diagnosis, and treatment. Therefore grab this multifunctional PPT now to convey your information on leukemia cancer impressively. 

Download Leukemia Science PowerPoint Templates And PowerPoint Backgrounds

Template 15

Another family of virus Hepatitis A can be influentially explained with this pre-designed template. Doctors, nurses, and other medical staff members can use it to create presentations for universities, hospitals, and other places depending upon their needs and requirements. It is also a good explanation tool for conferences and medical counseling sessions conducted in hospitals. The causes, vaccine reactions, side effects of the vaccine, diagnosis, treatment, and other aspects can be discussed efficiently with this neatly-designed template. The pre-designed elements of this template make your presentation work quick and a lot more convenient.

Download Hepatitis A Virus Medical Images For PowerPoint

Template 16

Showcase important information related to Herpes Simplex Virus using this slide. Explain its causes, risk factors, symptoms, vaccine, diagnosis, treatment, and other important aspects. Since this slide caters to the biology of viruses it will act as a great teaching tool in schools, medical universities, hospitals, and other places. Apart from this, it can be used by any medical practitioner and cell biologists depending upon what their project commands. 

Download Herpes Simplex Virus Medical Images For PowerPoint

Template 17

This pre-made template can be used to present amazing presentations on topics like virology, immunization, vaccination, and others. This template specifically targets Respiratory Syncytial Virus hence it can be used to give a thorough explanation of this virus, its types, symptoms, diagnosis and other aspects making it highly useful for the medical practitioners. 

Download Respiratory Syncytial Virus Medical Images For PowerPoint

Template 18

This presentation design is perfect for presenting strategies on the stop of growth and spreading of infection in humans. You can outline the entire structure of Measles and the infection caused by it using this template. Doctors can also use this template to educate their patients about Measles and prescribe an effective treatment for it. Nonetheless, the layout of this slide is designed professionally hence it is an ideal fir for medical students as well. 

Download Measles Virus Medical Images For PowerPoint

Template 19

Such templates are great for providing health lessons on various viruses, their causes, symptoms, and the like. They can be used by medical professionals, biology teachers, medical universities, and others as a contribution to preventing infections from spreading by creating awareness. Since this template is pre-designed it will function as a great tool to present medical presentations. 

Download Arena Virus Particle Structure Medical Images For PowerPoint

Template 20

Give a descriptive presentation on the highly contagious and deadly disease Smallpox using this slide. Showcase the structure of variola virus and its infection that leads to smallpox in humans. You can also present the history and evolution of this virus along with its treatment. Use it in conjunction with your medical presentation to create an impact. The high-resolution images used in each of the slides act as great teaching tools for educators, academicians, paramedical staff, and others.  

Download Smallpox Virus Medical Images For PowerPoint

Template 21

Many infectious diseases are becoming fatal among human beings because of the overgrowth of viruses. One such virus is the rubella virus causing red rashes throughout the body. This template aims at giving an overview of rubella, its causes, symptoms, and others. Thus, making it a highly resourceful design for your medical presentations. 

Download Rubella Virus Medical Images For PowerPoint

Template 22

We are bombarded with new infections every year some which are deadly and some which are not. This presentation aims at targeting a similar virus and its infections known as the RSV virus causing respiratory issues in children. The descriptive layout of this template makes it apt for presenting various medical presentations that are impressive and convince enough. These templates are specially designed to ease the work of the user by providing ready-made design and aesthetics. 

Download RSV Virus Medical Images For PowerPoint

Template 23

Mimivirus questions our understanding that viruses are small as this the largest and most complex virus ever found. This template can be used by presenters to explain the evolution, discovery, and analysis of mimivirus both from the scientific and medical perspectives. It showcases the complex structure of mimivirus and its characteristics which defy the conventional definitions of life. Using this template will help you explain the mimivirus more descriptively, thus making it a great template for your presentations. 

Download Mimi Virus Particle Structure Medical Images For PowerPoint

Template 24

This template shows the entire lifecycle of HIV and its replication, thus making it an outstanding explanation tool. This template is fully functional for doctors, medical universities, teachers, academicians, etc. looking to present important information on HIV and its infection. It is also a great tool to create awareness about this particular virus among the masses so that necessary steps can be taken to keep its spread in check. Apart from this biological experiment lab and genetic engineering projects can also use this template in whichever way they prefer. 

Download Replication Cycle Of Human Immunodeficiency Virus HIV Medical Images For PowerPoint

Template 25

While the world is battling with a pandemic Coronavirus and its mutated offsprings, we have designed this template to help you present some safety measures that will help fight with this virus, eating up the entire human race slowly and gradually. This template can be used to present information about the virus and safety measures to keep its spread in check like using sanitizers, wearing masks, observing social distancing, washing hands, not touching nose and face, etc. You can also use this template as a background for your presentations related to viruses. 

Download Fight With Virus Medical PowerPoint Templates And PowerPoint Backgrounds

Contemplating the origin of life is a fascinating topic for both scientists and the general public such as you and me. Understanding the evolutionary history of viruses and their life span can surely shed some light on this topic, which is what these 25 virus templates aim for. 

Although there is no clear explanation of the origin of these viruses, these have been present for millions of years among us humans. So, even a little bit of information can make a world of difference here. 

Download these templates to spark a sense of hope in these difficult and dark times where our lives and deaths are dependent on a VIRUS called Coronavirus or COVID 19.

Related posts:

• 10 Best Medical Google Slides Templates For Improving Lives
• Increase The Cohesiveness Of Workplace With Our Top 20 Organizational Culture Presentation Templates for PowerPoint!!
• Top 35 Change Management Templates To Transform Your Business WorkFlow
• 9 Beautiful Color Palettes for Designing Powerful PowerPoint Slides

Liked this blog? Please recommend us

Top 40 Medical, Healthcare Templates for Doctors and Nurses

Top 25 Drugs and Medicines PowerPoint Templates trusted by Medical Professionals

Top 30 Medical PowerPoint Slides for the Soldiers Fighting Against CoronaVirus!

Battling Coronavirus: Dumbledore’s Wise Message Guides Us in These Dark Times

The Complete COVID-19 PPT Presentation: Outbreak & Impact

This form is protected by reCAPTCHA - the Google Privacy Policy and Terms of Service apply.

Digital revolution powerpoint presentation slides

Sales funnel results presentation layouts

3d men joinning circular jigsaw puzzles ppt graphics icons

Business Strategic Planning Template For Organizations Powerpoint Presentation Slides

Future plan powerpoint template slide

Project Management Team Powerpoint Presentation Slides

Brand marketing powerpoint presentation slides

Launching a new service powerpoint presentation with slides go to market

Agenda powerpoint slide show

Four key metrics donut chart with percentage

Engineering and technology ppt inspiration example introduction continuous process improvement

Meet our team representing in circular format

• Ultimate Combo

• Sign Out Sign Out Sign In

238 Best Virus-Themed Templates for PowerPoint & Google Slides

With over 6 million presentation templates available for you to choose from, crystalgraphics is the award-winning provider of the world’s largest collection of templates for powerpoint and google slides. so, take your time and look around. you’ll like what you see whether you want 1 great template or an ongoing subscription, we've got affordable purchasing options and 24/7 download access to fit your needs. thanks to our unbeatable combination of quality, selection and unique customization options, crystalgraphics is the company you can count on for your presentation enhancement needs. just ask any of our thousands of satisfied customers from virtually every leading company around the world. they love our products. we think you will, too" id="category_description">crystalgraphics creates templates designed to make even average presentations look incredible. below you’ll see thumbnail sized previews of the title slides of a few of our 238 best virus templates for powerpoint and google slides. the text you’ll see in in those slides is just example text. the virus-related image or video you’ll see in the background of each title slide is designed to help you set the stage for your virus-related topics and it is included with that template. in addition to the title slides, each of our templates comes with 17 additional slide layouts that you can use to create an unlimited number of presentation slides with your own added text and images. and every template is available in both widescreen and standard formats. with over 6 million presentation templates available for you to choose from, crystalgraphics is the award-winning provider of the world’s largest collection of templates for powerpoint and google slides. so, take your time and look around. you’ll like what you see whether you want 1 great template or an ongoing subscription, we've got affordable purchasing options and 24/7 download access to fit your needs. thanks to our unbeatable combination of quality, selection and unique customization options, crystalgraphics is the company you can count on for your presentation enhancement needs. just ask any of our thousands of satisfied customers from virtually every leading company around the world. they love our products. we think you will, too.

Widescreen (16:9) Presentation Templates. Change size...

Medical symbol and virus over pink background

Close up of viruses on brown and gray background

Medical theme depicting isolated viruses with words virus on a purple background

White human with syringe injecting vacine, orange viruses, blue cell germ background

Red blood cells infected with blue viruses

Detailed 3D viruses spread on a blue background with wavy insertion

A skeleton and a virus in the picture

Close-up 3D HIV virus

Viruses in blood

A single green colored avian virus cell with nodes

Medical theme depicting humanoid having flu virus with green color

Tested sample of cells infected by HIV virus on black surface

Slide set consisting of rear view of hacker using laptop and credit card against virus background

Pink color shaped viruses with tint of green

Presentation having flu virus protection mask protective against influenza sickness viruses and disease sick sian woman wearing surgical face mask in public spaces healthcare banner panorama concept backdrop

Internet Virus

Transparent World map in white margins on dark red virus sign on red background

Presentation theme having woman wearing a real anti-pollution anti-smog and viruses face mask dense smog in air

Man with swine flu virus H1N1

Blue and green hive virus cells with black background, medicine

3D blue viruses on dark colored background with viruses shading in the background

Address bar with virus alert, virus depiction and virus word with cursor hovering over virus warning, https, red networking internet background

Human with New h1n1 influenza virus over white background

PPT theme with coronavirus corona virus prevention travel surgical masks and hand sanitizer gel for hand hygiene spread protection

Presentation featuring cybercrime hacking and technology concept - male hacker in dark room writing code or using computer virus program for cyber attack

PPT theme enhanced with medicine people and healthcare concept - female doctor or nurse wearing face protective medical mask for protection from virus disease with computer and clipboard calling on phone at hospital

Slide deck having medicine healthcare and pandemic concept - sad young female doctor or nurse wearing face protective mask for protection from virus disease sitting on floor at hospital

Antivirus artery bacteria biology blood cell in blue

Theme consisting of virus

Presentation theme featuring wanted hackers coding virus ransomware using laptops and computers cyber attack system breaking and malware concept

PPT theme consisting of corona virus prevetion face mask protection n95 masks and medical surgical masks at home

Slide deck with burglar wearing black hooded jacket against virus background

PPT layouts having virus

Slide deck having internet security concept open red padlock virus or unsecured with threat of hacking

PPT theme featuring coronavirus hand sanitizer gel to wash hands for flu virus prevention alcohol based antimicrobial disinfectant product for airport hospital healthcare and home panoramic banner background

3D anti-virus word with mouse connected to v letter and binary codes on network blue background

Presentation theme enhanced with doctor giving a senior woman a vaccination virus protection covid-2019 background

PPT layouts with doctor making a vaccination to a child

Red screen with a bio hazard sign on it

Presentation theme featuring picture showing woman sneezing on tissue on couch in the living-room

More virus templates for powerpoint and google slides:.

Company Info

Malicious PowerPoint files used to push remote access trojans

Bill toulas.

• January 24, 2022

Since December 2021, a growing trend in phishing campaigns has emerged that uses malicious PowerPoint documents to distribute various types of malware, including remote access and information-stealing trojans.

According to a report by Netskope’s Threat Labs shared with Bleeping Computer before publication, the actors are using PowerPoint files combined with legitimate cloud services that host the malware payloads.

The families deployed in the tracked campaign are Warzone (aka AveMaria) and AgentTesla, two powerful RATs and info-stealers that target many applications, while the researchers also noticed the dropping of cryptocurrency stealers.

Sliding malware into Windows devices

The malicious PowerPoint phishing attachment contains obfuscated macro executed via a combination of PowerShell and MSHTA, both built-in Windows tools.

The VBS script is then de-obfuscated and adds new Windows registry entries for persistence, leading to the execution of two scripts. The first one fetches AgentTesla from an external URL, and the second disables Windows Defender.

Additionally, the VBS creates a scheduled task that executes a script every hour, which fetches a PowerShell cryptocurrency stealer from a Blogger URL.

The malware payloads

AgentTesla is a .NET-based RAT (remote access trojan) that can steal browser passwords, log keystrokes, steal clipboard contents, etc.

It is executed by PowerShell and comes slightly obfuscated, while there’s also a function that injects the payload into an instance of “aspnet_compiler.exe”.

The second payload delivered in this campaign is Warzone, also a RAT, but Netskope doesn’t give many details about it in the report.

The cryptocurrency stealer is the third payload of this campaign, which checks the clipboard data with a regex that matches cryptocurrency wallet patterns. If found, it replaces the recipient’s address with one under the actor’s control.

The stealer supports Bitcoin, Ethereum, XMR, DOGE, and more. Netskope has published the complete list of IoCs (indicators of compromise) for this campaign, including all wallets used by the actors on this GitHub page .

PowerPoint becoming a problem

In December 2021, Fortinet reported about a similar DHL-themed campaign that also used PowerPoint documents to drop Agent Tesla.

Users must treat this document type with as much vigilance as they have when receiving Excel files since macro code in PP files can be equally as dangerous and catastrophic.

In this case, the actors also threw cloud services in the mix, hosting their malicious payloads on various legitimate platforms that are unlikely to raise any red flags with security tools.

As such, the most dependable protection measure is to handle all unsolicited communications with caution and also to keep macros on your Microsoft Office suite disabled.

Related Articles:

Millions of Docker repos found pushing malware, phishing sites

New Latrodectus malware attacks use Microsoft, Cloudflare themes

Fake job interviews target developers with new Python backdoor

CoralRaider attacks use CDN cache to push info-stealer malware

Fake cheat lures gamers into spreading infostealer malware

• Information Stealer
• Remote Access Trojan
• Previous Article
• Next Article

Post a Comment Community Rules

You need to login in order to post a comment.

Not a member yet? Register Now

You may also like:

Dell warns of data breach, 49 million customers allegedly affected

Citrix warns admins to manually mitigate PuTTY SSH client bug

Help us understand the problem. What is going on with this comment?

• Abusive or Harmful
• Inappropriate content
• Strong language

Read our posting guidelinese to learn what content is prohibited.

Respiratory Syncytial Virus Infection in Older Adults: An Update

• Review Article
• Open access
• Published: 07 May 2024

Cite this article

You have full access to this open access article

• Franco Alfano 1 ,
• Tommaso Bigoni 1 ,
• Francesco Paolo Caggiano 1 &
• Alberto Papi   ORCID: orcid.org/0000-0002-6924-4500 1  

120 Accesses

1 Altmetric

Explore all metrics

Respiratory syncytial virus (RSV) infection represents one of the most common infections during childhood, with significant morbidity and mortality in newborns and in the early years of life. RSV is a common infection throughout all age groups, largely undetected and underestimated in adults, with a disproportionately high impact in older individuals. RSV infection has a wide range of clinical presentations, from asymptomatic conditions to acute pneumonia and severe life-threatening respiratory distress, including exacerbations of underlying chronic conditions. Overall, the incidence of RSV infections requiring medical attention increases with age, and it is highest among persons ≥ 70 years of age. As a consequence of a combination of an aging population, immunosenescence, and the related increased burden of comorbidities, high-income countries are at risk of developing RSV epidemics. The standard of care for RSV-infected patients remains supportive, including fluids, antipyretics, and oxygen support when needed. There is an urgent need for antivirals and preventive strategies in this population, particularly in individuals at higher risk of severe outcomes following RSV infection. In this review, we describe prevention and treatment strategies for RSV illnesses, with a deep focus on the novel data on vaccination that has become available (Arexvy, GSK, and Abrysvo, Pfizer) for older adults.

Similar content being viewed by others

Respiratory syncytial virus infection in older adults: an under-recognized problem.

Respiratory Syncytial Virus Infection: An Update

The Future of Respiratory Syncytial Virus Disease Prevention and Treatment

Avoid common mistakes on your manuscript.

1 Epidemiology, Virology, and Immunopathology

1.1 introduction.

Respiratory syncytial virus (RSV) is a ubiquitous respiratory virus belonging to the Pneumoviridae family, genus Orthopneumoviridae . There are two subgroups (A and B), differing from each other in their molecular structure. Like other respiratory viruses, RSV infection results in annual recurring events (seasonal epidemics). RSV infection represents one of the most common infections during childhood, with significant morbidity and mortality in newborns and in the early years of life [ 1 ]. In recent decades, epidemiological data have reinforced the evidence of the many faces of RSV infection throughout all age groups, with a disproportionately high impact in elderly individuals. RSV infection has a wide range of clinical presentations, from asymptomatic infections to severe lower respiratory tract infections (LTRIs), including exacerbations of underlying chronic conditions. Overall, RSV-related acute respiratory infections (RSV-ARIs) are largely undetected in adults and substantially underestimated. Currently, two monoclonal antibodies (palivizumab and nirsevimab) are approved and available for preventing RSV infection in the high-risk infant population, whereas no such option is available for adults. Recently, active immunization has been approved in adults based on the efficacy of candidate vaccines in phase III studies. In this article, maintaining a deep focus on elderly individuals and people with comorbidities, we discuss the latest epidemiological data about RSV, its virology and immunopathology, and the clinical characteristics and therapeutic and preventative perspectives of RSV infection.

1.2 Source and Selection Criteria

Our search sites included references in PubMed and Google Scholar between 1957 and 2023. The main search terms included “RSV” and “respiratory infections”, in conjunction with “therapeutics”, “vaccine”, “epidemiology”, “adults”, “elderly”, “frail”, and “comorbidities”. We searched for recent guidelines and consensus statements. We included observational and animal studies if clinically relevant. Finally, we searched ClinicalTrials.gov for updated clinical trial information.

1.3 Epidemiology

In 2015, the Global Burden of Disease (GBD) study estimated 1.7 million deaths caused by LTRIs, with RSV representing one of the important viral pathogens [ 2 ]. RSV has a seasonal pattern of infectivity, commonly seen in respiratory viruses, including influenza, with annual recurrence. In temperate climate countries, it spreads throughout the winter season, with a peak between December and January, whereas in tropical countries, it circulates in the summer season [ 3 ]. Either a single subgroup or both (A and B) remain each season, determining reinfection and seasonal outbreaks [ 3 ]. Reinfections are common throughout life due to a short-term, or incomplete, immunity response. Antigenic variations are considered less important, at variance with other respiratory viruses such as influenza [ 4 ]. Before the coronavirus disease 2019 (COVID-19) pandemic, RSV followed a predictable seasonal pattern of infection. During the pandemic, due to the reduced spread of infections related to generic hygiene procedures such as social distancing, wearing face masks, and hand washing/disinfecting, all respiratory viral infection rates dramatically decreased, especially the clinical manifestations of RSV and influenza. Notably, there was a rebound of viral infections following the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic season [ 5 ]. The concept of “immunity debt” has been proposed for this resurgence of cases, which caused a heavy burden on healthcare services defined as a “tridemic”, a triple threat from the increasing spread of SARS-CoV-2, flu, and RSV at risk of overwhelming the healthcare systems [ 5 ]. After the SARS-CoV-2 pandemic period and the lifting of public health and social measures, a greater number of RSV cases were observed in different countries, with out-of-season epidemics and with a delayed surge of RSV, compared with the usual seasonality [ 6 ].

The highest burden of RSV infections occurs in children < 5 years old (with a global incidence of 17 per 1000 people) and older adults aged > 70 years (incidence of 6.3 per 1000 people) [ 5 ]. A global systematic analysis recently conducted in children aged < 5 years old estimated that 33.0 million RSV-LTRIs occurred in 2019, of which, 6.6 million occurred in infants 0–6 months old, with more than 95% of RSV-LRTIs occurring in low- and middle-income countries [ 7 ]. In children aged < 5 years, 3.6 million RSV hospital admissions were estimated, with 26,300 in-hospital deaths globally [ 7 ]. RSV accounts for as much as 70% of all childhood respiratory infections, with almost all children infected with RSV by the age of 3 [ 8 , 9 ]. Known risk factors for severe RSV infection in younger people include prematurity, age < 2 months, underlying chronic lung or heart diseases, serious neurological or metabolic disorders, Down’s syndrome, immune deficiency, crowded living conditions, and indoor smoke pollution.

Data on RSV infection in elderly individuals and in people with comorbidities are some decades behind the robustness of the paediatric evidence, although they have recently had exponential growth. The RSV burden in three European countries in both healthy older adults and adults with comorbidities is comparable to that caused by influenza [ 10 ]. RSV-ARI is the third most commonly identified viral cause of hospitalization, mostly in adults aged > 65 years old, with less than 1% of adults with RSV infection requiring hospitalization [ 3 ]. Data on adults from developing countries are scarce. No significant difference in sex or economic status has been reported in the incidence of RSV infection, even when tropical and subtropical regions were considered [ 11 , 12 ].

Prospectively, in high-income countries, it is expected in 2025 that the number of RSV-ARIs in older people > 65 years could reach 10 million cases, 800,000 hospitalizations, and 74,000 in-hospital deaths [ 10 ]. A recent meta-analysis conducted by Savic et al. analysed 21 different studies regarding RSV infections in people aged 60 years and older in high-income countries, highlighting that, in 2019, the RSV-ARI attack rate was 1.62% [ 10 ]. The RSV-ARI hospitalization rate was estimated to be 0.15%, while the RSV-ARI in-hospital case fatality rate (hCFR) was 7.13% [ 10 ]. For comparison, each year influenza causes between 3 and 5 million severe cases, with 290,000–650,000 deaths globally, most of them occurring in older patients [ 13 ]. The influenza mortality rate in people aged > 70 years old is 16.4 per 100,000 people, compared to 1.9 in the general population [ 14 ]. Similarly to RSV, the population at higher risk of severe disease or complications due to influenza infection are children under 5 years of age, older people, individuals with chronic medical conditions (i.e. cardiorespiratory, renal, or immunosuppression conditions), and pregnant women [ 15 ].

RSV infection has been increasingly identified as a cause of respiratory viral diseases in adults with comorbidities, including cardiopulmonary diseases. A meta-analysis by Shi et al. considered 20 studies on RSV-ARIs in adults with comorbidities, 18 from developed countries and two from developing countries, and ten in adults aged > 18 years and ten in older groups of > 50 years [ 2 ]. The analysis reported an incidence rate for RSV-ARI in adults with comorbidities (e.g. cystic fibrosis, chronic heart failure [CHF], chronic obstructive pulmonary disease [COPD] immunocompromised status) of 30.3 per 1000 persons per year/season [ 2 ]. The hospitalization rate in CHF or COPD adults aged > 65 years was 13.2 per 1000 persons per year, with an hCFR of 11% [ 16 ].

Indeed, it has been estimated that as a consequence of a combination of an aging population, immunosenescence, and the related increased burden of comorbidities, high-income countries are at risk of developing RSV epidemics [ 17 ]. Notably, clinicians for a long time have not been considering RSV infection as a potential cause of hospitalization and relevant morbidity in adults. This, combined with the lack of specific antiviral treatment, has discouraged physicians from performing RSV diagnostic testing and contributed to the under recognition/estimation of the real impact of RSV (particularity in at-risk populations) [ 10 ]. Indeed, to date, few ad hoc RSV surveillance systems are in place to assess the real impact of RSV infection and to raise awareness of the risks of RSV infections in sensitive populations [ 17 ]. In recent years, RSV testing has substantially increased in relation to more efficient and affordable detection methods, such as the molecular polymerase chain reaction (PCR) technique [ 3 ].

In a recent European study, almost 40% of all RSV-associated hospitalizations occurred in patients aged 65 years and older [ 17 ]. Of the 158,000 RSV-associated hospital admissions among adults older than 18 years old [ 17 ], 92% (145,000) occurred in patients older than 65 years of age (Fig. 1 ). Adults aged 75–84 years showed the highest annual frequency of RSV hospitalization, accounting for 75,000 cases/year, at a rate of 2.24 per 1000 adults annually, with the highest rate among elderly individuals > 85 years of age [ 17 ]. Comparable data have been reported in the United States (US), with a burden of 159,000 RSV hospitalizations in adults > 65 years of age [ 18 ]. The overall mortality for patients admitted for RSV is 6–8%, accounting for 25% of the excess winter mortality [ 3 ]. Data from Southern and Eastern Europe are still scarce. Moreover, even if data available for RSV hospital admission are likely to reflect the overall burden of the infection, to date, the estimated burden of the disease in the general population is still uncertain.

(data from [ 17 ]).

Geographical distribution of the estimated annual respiratory syncytial virus-associated hospitalizations in European Union countries (including the United Kingdom) and Norway in patients aged > 65 years old

Between 10% and 31% of adults hospitalized for RSV infection require intensive care support, while 3–17% of them require mechanical ventilation. Of all high-risk patients (with cardiopulmonary disease or immunodeficiency) infected by RSV, 32% will require hospitalization and 26% will need intensive care support [ 19 ]. Data indicate that mortality rates range from 11 to 18% in hospitalized adults 65 years of age and older with RSV infection [ 2 , 20 ], with an estimated 13% RSV-related case fatality for patients with cardiopulmonary disease among high-risk European adults [ 19 ].

In general, RSV infections occur more frequently in patients with underlying chronic lung diseases. In patients with obstructive lung diseases, RSV is one of the major triggers of acute exacerbations of asthma and COPD [ 3 ]. RSV is the second most common respiratory virus detected in acute exacerbations of COPD, accounting for up to 15% of exacerbations. In COPD patients, the clinical presentation, radiological findings, length of stay, hospitalization, intensive care unit (ICU) admission, and mortality rates of RSV infection are similar to those of influenza [ 21 ]. RSV is also a major risk factor for developing asthma exacerbations, particularly in patients hospitalized for RSV-ARIs in infancy [ 4 ]. Moreover, RSV can induce bronchial hyperresponsiveness, contributing to the pathogenesis of asthma in infancy [ 22 ].

1.4 Virology and Immunopathology

RSV is a respiratory virus belonging to the Pneumoviridae family, Orthopneumoviridae genus. RSV is a single-stranded negative-sense RNA virus containing an approximately 15,200-nt genome and encoding 11 proteins (Fig. 2 ) [ 23 ]. Proteins G and F are the two most relevant surface antigenic proteins, accounting for attachment and fusion, respectively, to host cells. RSV is categorized into two antigenic subtypes, A and B, based on the second hypervariable region of the G gene [ 4 , 24 ]. RSV-A and RSV-B subtypes may cocirculate during an outbreak; RSV-A represents the predominant strain in most years [ 4 ]. Reinfection is frequent and can occur throughout life, while the severity of RSV-ARI tends to diminish after subsequent exposure [ 4 ].

(Reproduced with permission from [ 3 ]).  ssRNA single-stranded ribonucleic acid

Structure and genomic RNA of respiratory syncytial virus

RSV spreads through respiratory droplets or fomites. RSV primarily infects polarized ciliated human airway epithelial cells (hAECs) [ 25 ], reaching the upper (URT) and lower respiratory tracts (LRT). hAEC infection determines morphological alterations of infected cells, cilia loss, mucus hypersecretion, and syncytia formation (thus, the name of syncytial virus) [ 4 ]. The G protein (RSV G) is responsible for virus attachment, binding to receptors such as nucleolin, CX3C motif chemokine receptor 1 (CX3CR1), Heparan Sulfate ProteoGlycans (HSPGs), and Intercellular Adhesion Molecule 1 (ICAM-1). After RSV G connects RSV to epithelial cells, RSV F protein merges with the surface membrane and enters through pores into the cytoplasm. Viral entry and infection are catalysed by the prefusion F protein after a conformational change into a post-fusion conformation, fusing the virion to host cells. Herein, viral RNA initiates transcription and viral replication [ 23 ].

During the first phase of infection, host cell pattern recognition receptors (PRRs) recognize RSV and initiate a signalling cascade resulting in the expression of interferon (IFN) molecules, upregulating major histocompatibility complex I (MHC-I), NLR family CARD domain containing 5 (NLRC5), and IFN-β [ 4 ]. During the later stage of RSV infection, Toll-like receptor 3 (TLR3) binds to viral RNA, activating the transcription of Nuclear factor-κB (NF-kB) and type I IFNs. The upregulation of type I IFN predisposes cells to an “antiviral state”, which restricts viral replication and warns and activates uninfected cells [ 4 ]. In mammalian models and humans, RSV proteins such as NS1, NS2, G RSV, and F RSV reduce type I responses, while several RSV proteins can interfere with type III IFNs located on hAECs, facilitating viral replication [ 23 ]. hAEC-infected cells release chemo-attractants and adhesion molecules such as tumour necrosis factor (TNFα), C-X-C motif chemokine ligand 6 (CXCL6), interleukin (IL)-1β, IL-6, IL-8, chemokine ligand 2 (CCL2), granulocyte-monocyte colony stimulating factor (GM-CSF), Macrophage inflammatory protein-1 alpha (MIP-1α), ICAM-1, and MHC-I/II, thus fully activating innate and adaptive immune responses [ 4 ]. Each different RSV protein plays a role in infection and in eliciting an immune response. NS1 and NS2 are involved in immune modulation by interacting with different immune signalling pathways, including the JAK/STAT suppressing pathway, and with the host’s gene expression and activation pathways, including NF-kB. In vitro and in vivo, NS1 and NS2 induce necroptosis of hAECs, an inflammatory programmed cell death, and subsequently inhibiting the classic apoptosis pathway [ 26 ]. RSV proteins in infected hAECs not only interfere with intrinsic and classical immune pathways but also impair the activation of several genes involved in the production of cytokines and chemokines, which are critical for the recruitment of innate and adaptive immune cells [ 26 ].

Indeed, both innate and adaptive immune responses are elicited by RSV infection; they both contribute to the pathogenetic mechanisms related to the infection [ 23 ], as summarized in Fig. 3 [ 21 ]. RSV innate immune responses involve polymorphonuclear leukocytes (PMNs, such as neutrophils and eosinophils), alveolar macrophages (AMs), natural killer (NK) cells, and dendritic cells (DCs).

Pathogenesis of RSV infections, involving the innate and adaptive immune response. AMs alveolar macrophages, DCs dendritic cells, hAECs human airway epithelial cells, NKs natural killers, PMNs polymorphonuclear cells, RSV respiratory syncytial virus

Neutrophils can migrate into tissues during acute viral infections and are involved in virus identification and elimination, antigen presentation, recruitment of proinflammatory cells, and cytokine production. Neutrophil activity during RSV infection consists of phagocytosis, degranulation, and NETosis, i.e. a neutrophil-death inflammation signalling pathway. Polymorphonuclear cells exhibit a bivalent role during RSV infection and could lead to more severe and symptomatic infections [ 4 ].

Eosinophils have phagocytic and antigen-presenting activity. RSV-infected in vitro hAECs secrete chemoattractant mediators such as CCL5 or MIP-1α, leading to eosinophil recruitment to the site of infection [ 4 ]. Eosinophils activate signalling cascades, resulting in increased expression of type I IFNs such as IFN-β. Eosinophils contribute to viral elimination by degranulation and secretion of RNA-degrading enzymes, such as eosinophilic cationic protein (ECP) [ 4 ]. Excessive recruitment of eosinophils may result in tissue damage and an unbalanced T cell response towards a T2-high phenotype [ 4 , 22 ]. Indeed, infants with severe RSV disease have a high Th2/Th1 (T helper) ratio profile and an increased risk of developing asthma [ 22 , 23 ].

NK cells are crucial to restrict viral spread in the early stages of infections, given their cytotoxic and immunological activities. In the later stages of infection, NK cells switch to a regulatory phenotype to limit immune cell-mediated lung inflammation [ 4 ]. Functional monocytes migrate into the lungs during viral infections, and their role is pivotal for protection, immune regulation, and supply to the macrophage population during the acute phases of viral infection [ 4 ]. Lung DCs are professional antigen-presenting cells that are chief producers of type I IFNs and bridge innate and adaptive immune responses during viral infection. DC depletion may result in increased viral load [ 4 , 23 ].

Adaptive immune responses to RSV occur via B cell and T cell activation, and B cells prime the production of virus-specific antibodies, neutralizing the virus and thus preventing RSV cell entry. B cells produce antibodies against RSV F (to both the prefusion and post-fusion structures) that are highly neutralizing and cross-react with both RSV-A and RSV-B subtypes [ 27 ]. Unfortunately, RSV-specific B cells rapidly decrease once the infection is over, usually within months after exposure, due to an immunosuppressive effect of RSV on the generation of memory T cells [ 4 ]. CD8+ cytotoxic T cells can directly kill RSV-infected cells, while CD4+ T cells enhance B cell activation and antibody production [ 23 ]. Older adults have comparable RSV antibody responses to younger people, even if they are more susceptible to severe RSV infections, indicating that other immunological parameters, such as dysfunctional T cells, should be considered to account for the immunological deficiencies associated with immunosenescence [ 4 ].

In childhood, the mechanisms of RSV-associated diseases are considered related to the immaturity of the defensive system; in analogy, in elderly people, immunosenescence plays a relevant role in increasing susceptibility to infection and increasing the risk of severe output of the infective event. Immunosenescence refers to the diminished efficiency of the innate and adaptive immune systems due to biological aging [ 28 ]. It is a complex condition accounting for a series of alterations in immune homeostasis and cell regulation, resulting, among others, in increased susceptibility to severe infections, poor vaccine responses, and a higher likelihood of long-term sequelae [ 29 ]. Older adults show reduced viral clearance and mucus production, which favour the occurrence of airway infections [ 4 ]. In the elderly population, B cell and antibody responses are lower in quantity and less efficient than in younger individuals. Similarly, the T cell repertoire is poorer and has low functioning, with dysregulation of cytokine production and fibrosis of lymph nodes [ 29 ]. These factors contribute to increasing susceptibility to infectious diseases. Indeed, influenza-related deaths occur in 70–90% of adults older than 65 years of age, while pneumococcal disease mortality in older adults (15–30%) is higher than that in the younger population [ 29 ]. In addition, as a consequence of the dysregulation of immune responses due to immune senescence, elderly individuals express a lower rate of seroconversion after vaccination than younger individuals, as documented for influenza vaccines [ 30 ].

2 Clinical Presentation, Risk Factors, and Comorbidities in Adult Patients

In general, RSV-ARIs are not clinically distinguishable from those related to other respiratory viruses. There is a wide range of clinical presentations (Table 1 ), from asymptomatic conditions to acute pneumonia and severe life-threatening respiratory distress [ 31 ]. In adults, asymptomatic infections are less frequent than in younger patients (< 5%). The majority of adults develop signs of URT infection, such as rhinorrhoea, nasal congestion (22–78%), or pharyngodynia (16–64%), within 5 days of infection [ 3 ]. LRTIs can cause cough (85–95% of cases), wheezing (33–90%), and dyspnoea (51–93%), reflecting RSV direct/indirect damage to the lower tract [ 3 ]. Nonspecific systemic symptoms are fever, asthenia, and anorexia (48–56%), which could vary in intensity and severity [ 3 ], although they occur less commonly than in influenza infection. Unlike influenza virus infections, whose clinical expression peaks at 2–3 days after the onset of the first symptom, RSV infection typically develops symptoms from 4 to 7 days after exposure, peaking between 7 and 13 days [ 32 ].

RSV LRTIs can cause pneumonia and exacerbations of chronic airway diseases such as asthma or COPD [ 33 ]. Respiratory failure has been reported in 8–13% of older adults hospitalized for RSV, with a mortality of 2–5% [ 34 ]. RSV infections can be complicated by concomitant bacterial or viral respiratory coinfection in up to 21–23% of cases, with the former pathogen coinfection being associated with an enhanced risk of death and severe RSV disease [ 3 ]. During the recent COVID-19 pandemic, significant RSV coinfection was demonstrated in patients with SARS-CoV-2 infections. The most common coinfections were rhinovirus/enterovirus (6.9%), RSV (5.2%), and non–SARS-CoV-2 Coronaviridae (4.3%) [ 35 ].

Clinical manifestations of RSV infection in the elderly are hardly distinguishable from those of influenza or other respiratory viruses, but some symptoms may be more suggestive for one of the pathogens. High fever is more frequently associated with influenza. Similarly, malaise, asthenia, and myalgia, as well as gastrointestinal symptoms are less common in RSV infection than during influenza episodes [ 34 ].

Compared to influenza adults, adults hospitalized with RSV present a longer length of stay (6.0 days vs 3.6 days) [ 17 ] and increased morbidity. In a study conducted on adults in patients hospitalized for influenza-like illness during three consecutive seasons, 15% of RSV-positive patients were admitted to the ICU, and 8% died. The percentages were similar in the influenza-infected individuals. RSV patients were significantly more likely than patients with influenza or without RSV to develop pneumonia (44% vs 28% and 26%, respectively) [ 36 ].

RSV infection usually occurs more than once in life. Although our knowledge of the burden of RSV in the elderly has increased [ 1 , 5 ], it is still lacking compared to the vast literature available for RSV in children [ 2 ]. Indeed, RSV was not considered a potentially serious problem in older adults until the 1970s, when outbreaks of RSV infection occurred in long-term care facilities [ 12 , 37 ]. Overall, the incidence of RSV infections requiring medical attention increases with age, and it is highest (199 episodes per 10,000) among persons ≥ 70 years of age [ 38 ].

2.1 RSV Infections in Older Patients with Chronic Diseases

Many hospitalized RSV infections involve adults with chronic medical conditions. In these cases, even when the RSV infection is clinically mild, it can result in hospital admission, serious complications, and death [ 10 ]. Advanced age, pneumonia, ventilator support, and secondary bacterial infection are all associated with an increased risk of death among hospitalized patients with RSV [ 17 ].

Viral infections, particularly rhinovirus and RSV, are commonly associated with acute exacerbations of asthma [ 39 ] and have been claimed to contribute to the development of asthma in preschool children [ 40 , 41 ]. A prospective study with a cohort of 206 children demonstrated that severe RSV bronchiolitis in the first year of life is followed by a diagnosis of childhood asthma by the seventh birthday in nearly half of children. High asthma rates (48% by age 7 years) have been reported after RSV bronchiolitis in childhood [ 42 ].

RSV infection is an important cause of COPD exacerbation; it has been identified with variable frequencies ranging from 0.8 to 22% of acute cases according to the different diagnostic tools [ 31 ].

A multicentre study was conducted in 28 hospitals between January 2015 and December 2018 in the Republic of South Korea in a cohort of 1177 patients hospitalized with a diagnosis of acute exacerbation of COPD. The most commonly detected viruses were rhinovirus (11%) and influenza virus A (11%), followed by RSV (4.3%) [ 43 ].

In a post hoc analysis of two longitudinal studies that examined RSV infection in high risk adults for ≤ 2 RSV seasons, an increased risk of illness with RSV among patients with COPD was associated with exposure to children and the presence of CHF [ 44 ]. The association between exposure in children and the risk of acquiring RSV illness is not surprising because respiratory secretions of infants with primary infections contain high viral titres of RSV for relatively long periods, and infectious fomites may contaminate environmental surfaces [ 45 ].

In a secondary analysis of a multicentre prospective study in hospitalized patients with acute respiratory diseases in Canada, hospitalized patients with COPD who were RSV positive had a significant morbidity compared to individuals with influenza infection. In hospitalized patients with COPD and RSV infection, 24% needed non-invasive ventilation (vs 11% with influenza) and 18% needed ICU admission. Once in the ICU, half of the patients with RSV required mechanical ventilation. A lower mortality rate (2.8%) was observed among RSV-positive versus influenza-positive individuals. However, a significantly higher proportion of patients with RSV received non-invasive ventilation (23.6% with RSV vs 11.2% with influenza), which may have affected the likelihood of survival in the context of underlying COPD [ 46 ].

The association between cardiopulmonary diseases and the severity of RSV-associated respiratory disease is likely multifactorial and includes changes in immune function, hypoxia, and fever stress and possible prothrombotic changes induced by the infection and the related inflammatory conditions. With disruption of endothelial function, the inflammatory response can lead to plaque destabilization and rupture and thus contribute to acute coronary syndrome, especially in patients already at risk. In a large multicentre review of 607 patients hospitalized with RSV in Hong Kong, 14% of patients had cardiovascular complications; likewise, 13.3% of 547 influenza virus-positive patients had cardiovascular complications. Cardiovascular complications (heart failure, atrial fibrillation, acute coronary event) occurred in 19.4% of adults (18–65 years of age) with RSV infection, as well as 21.3% of immunocompetent elderly (> 65 years of age) and 25.6% of patients with COPD [ 47 ]. In a Canadian study with 22% of patients hospitalized for RSV infection experiencing cardiovascular complications (14% CHF exacerbation, 8% new arrhythmia, 2% stroke, and 1% myocardial infarction), 52% of patients had a past medical history of cardiac disease [ 48 ]. Acute cardiovascular events were the direct cause of mortality in 16.7% of the 72 patients with RSV who died within 60 days of hospital admission [ 33 ].

A number of high-risk factors for RSV infection have been identified in haematopoietic stem cell transplantation, such as male sex, type of transplant (i.e. allogeneic), cytomegalovirus seropositivity, and engraftment status [ 4 , 37 ]. Infection with RSV is also of special concern in lung transplant recipients [ 26 ]. The estimated incidence of community-acquired respiratory virus infections in lung transplant recipients is 15–50 cases per 100 patient-years, and RSV accounts for 19% of these infections (i.e. 2–10 per 100 patient-years) [ 49 ].

3 Diagnostic Tools and Innovation

Four principal methods of diagnosing RSV acute infection are currently available: viral culture; antigen detection by immunofluorescence assay (IFA) or enzyme immunoassay (EIA); RNA detection by reverse transcription-PCR (RT-PCR); and serological assessment of RSV-specific Immunoglobulin M (IgM) antibodies or a significant rise in RSV-specific IgG antibodies between acute- and convalescent-phase sera. The latter method provides only a retrospective diagnosis [ 50 ]. Molecular techniques, such as nucleic acid amplification tests, which can detect very low viral titres, have high diagnostic accuracy in adults and provide rapid results. Reverse transcriptase real-time PCR (RT-PCR) has become the reference diagnostic method for RSV detection [ 51 , 52 ].

Nearly all recent RSV incidence estimates have been obtained by RT-PCR testing of nasal or nasopharyngeal (NP) swabs [ 53 ]. The advantages of adding multiple tools for detection are questionable [ 54 ]. NP swabs have become a common self-administered tool for detecting viral infection during the COVID-19 pandemic; thus, currently, obtaining accurate epidemiological/diagnostic data has become simpler.

In the case of respiratory symptoms appearing in an elderly individual, early detection of RSV would allow a more effective containment of virus spread and prevention of outbreaks, as we learned from the recent COVID-19 pandemic. Additionally, the opportunity to use swabs to simultaneously identify multiple respiratory pathogens would enable a faster and more targeted management approach. Therefore, considering the simplicity of (and familiarity with) NP swab collection in the general population (particularly among healthcare professionals and caregivers), the use of tools such as nasal and NP swabs should be encouraged, particularly in nursing homes and long-term care facilities, where the most vulnerable individuals reside and are at higher risk of severe clinical manifestations.

Radiological findings associated with RSV infection are usually nonspecific and nondiagnostic, particularly on chest X-ray.

In an observational and retrospective study, hospitalized adults with laboratory-confirmed RSV infection underwent chest radiography at admission. The chest radiography was abnormal in 50% of patients, with consolidation (48%) and ground glass opacity (GGO) in a single unilateral lower zone (40%) being the most frequent findings. [ 55 ].

Computed tomography may reveal pulmonary nodules and GGOs [ 56 ]. In general, imaging studies should be considered in most severe cases for differential diagnosis. In children with RSV infection (1 day to 10 years [median 7 months]), chest X-ray demonstrates radiological findings of central pneumonia and peribronchitis or the absence of abnormalities in equal proportions [ 57 ]. In an observational study in adults, lung bilateral involvement was less frequently reported in RSV cases than in other non-RSV viral infections [ 58 ].

The diagnosis of RSV infection in immunocompromised individuals is also associated with findings such as GGOs, nodular lesions, and signs of organizing pneumonia. In contrast to RSV, tree-in-bud opacities are frequently reported in influenza infections [ 59 ].

4 Management and Prevention

The standard of care for RSV-infected patients remains supportive, including fluids, antipyretics, and oxygen support when needed [ 60 ]. In children, only short-term clinical benefits are achieved with the use of available drugs and antivirals, with little or no effect from pharmacotherapy-based bronchodilators and glucocorticoids. There is no recommendation for the routine use of 3% nebulized hypertonic solution in children experiencing acute bronchiolitis [ 61 ]. Two antibody drugs, palivizumab and nirsevimab, have been approved for preventing RSV infection in infants. No such option is currently available for the treatment of RSV infection in adults. Therefore, there is an urgent need for antivirals and preventive strategies in this population, particularly in individuals at higher risk of severe outcomes following RSV infection. In the next sections, we will analyse some of the molecules currently under investigation for the treatment of RSV infection, as well as novel data for the prevention of RSV infection in adults/elderly people.

4.1 Pharmacological Treatment

A number of treatments (mainly antivirals) have been developed and tested in RSV acute infections. They have been recently reviewed in detail [ 62 ]. Here, we summarized only some of the relevant data and antiviral drugs currently in clinical development.

4.1.1 Ribavirin

The only antiviral treatment for RSV approved by the Food and Drug Administration (FDA) in infants is ribavirin. It inhibits replication of both RNA and DNA viruses. Ribavirin can be administered intravenously, orally, and by aerosolization and has often been given in combination with intravenous immunoglobulin.

Compared to the original inhaled formulation, the oral formulation is equally effective and cheaper; thus, it is the preferred route of administration. The efficacy data are controversial, and use is restricted to life-threatening RSV LRTIs and lung transplant recipients [ 63 ].

4.1.2 Presatovir (GS-5806)

GS-5806 is an oral small molecule that inhibits RSV entry at low nanomolar concentrations by blocking viral-envelope fusion with the host cell membrane. A phase I study in humans showed no adverse events. The study was conducted in healthy adults experimentally infected with a clinical strain of RSV and showed a significant reduction in the viral load, along with a reduction in mucus production and the total symptom score [ 64 ]. A phase IIb study conducted in patients undergoing lung transplantation found no efficacy in reducing the viral load, symptom improvement, or prevention of lung function deterioration in lung transplant recipients infected with RSV [ 49 ].

4.1.3 Sisunatovir (RV521)

RV521 is an orally bioavailable inhibitor of RSV fusion to host cells. Oral bioavailability in preclinical species ranged from 42 to > 100%, with evidence of highly efficient penetration into lung tissue. In healthy adult human volunteers experimentally infected with RSV, a potent antiviral effect was observed with a significant reduction in both viral load and symptoms [ 65 ].

4.1.4 Ziresovir (AK0529)

Ziresovir is an RSV fusion inhibitor that reduces cytopathic effects in HEp-2 cell cultures [ 66 ] infected with both RSV A and B strains [ 67 ]. In a phase II study, AK0529 was well tolerated in hospitalized RSV-infected infant patients, and treatment with AK0529 2 mg/kg bid reduced viral load [ 68 ].

4.2 Prevention

4.2.1 hygiene measures.

As for other respiratory viruses, RSV is classically spread through inhalation of aerosolized droplets and, especially in children, by contact with fomites. Good hygiene practices therefore have a fundamental role in limiting the transmission of this infection. Multiple strategies could be applied, such as careful and periodic hand washing, social distancing, especially outside the house and with non-family members, home isolation of people presenting respiratory symptoms, covering coughs and sneezes with a single-use tissue or the elbow, using easily cleanable toys if working with children, cleaning frequently touched surfaces with bleach solution or disinfectants, and wearing a facial mask in public situations when social distancing is not feasible. Furthermore, structural and procedural measures should be implemented for the frailest population, such as those living in long-term care facilities. During the COVID-19 pandemic, the broad application of these rules deeply impacted the circulation of all respiratory viruses, including RSV, as reported by the Centers for Disease Control and Prevention (CDC). In the 4 years before the COVID-19 pandemic, the weekly percentage of positivity of RSV detection tests in the US usually rose from 3% to 12.5–16.7% between October and December. In contrast, from January to April 2020, it fell from 15.3% to 1.4% and persisted < 1% weekly during the next year. From October 2020 to April 2021, the cumulative incidence of hospitalization related to RSV disease decreased to 0.3 cases per 100,000 people, starting from 27.1 and 33.4 in the preceding two seasons (Fig. 4 ) [ 69 ]. In addition, COVID-19 spread in nursing homes and long-term care facilities was deeply reduced by procedural and structural measures, such as protected zones for family visits, entry restrictions, and COVID-19 isolation areas [ 70 ].

Evolution of RSV epidemiology during the COVID-19 pandemic. Reproduced from Ref. [ 69 ] (Content source: Centers for Disease Control and Prevention). COVID-19 coronavirus disease 2019, RSV respiratory syncytial virus

Preventive hygiene measures should therefore be performed, especially in older people, those with social contact with children and frail patients.

4.2.2 Passive Immunization

The main purpose of passive immunization consists of reducing the spread of RSV from the URT to the LRT using anti-RSV antibodies, limiting the severity of the infection to an URT infection. Currently, passive immunization is an option exclusively for high-risk infants [ 71 ]. Studies are needed to evaluate the efficacy and cost-effectiveness of these drugs in adult patients to provide more preventive opportunities, especially for those with a contraindication to vaccination.

4.2.2.1 Palivizumab

Palivizumab, an RSV-specific monoclonal antibody approved for the prevention of RSV infection, is effective in reducing RSV hospitalization rates by approximately 60%. The use is indicated in infants at risk (overall in 3% of the total infant population), e.g. those who are born prematurely or have underlying conditions (chronic lung disease, congenital heart disease, immunodeficiencies, or other severe chronic illnesses). This antibody protects against severe disease; it is expensive and therefore, it is only used in high-income countries of high-risk preterm infants. Palivizumab exhibits no efficacy in the treatment of RSV infection [ 72 ].

Some evidence has shown a safe and well-tolerated profile of this drug in immunocompromised adults [ 73 , 74 , 75 , 76 ], although it has been tested in small studies and there is no approved indication.

4.2.2.2 Nirsevimab

Nirsevimab is a derivative antibody from a precursor of the prefusion F protein; it has been engineered to increase efficacy and prolong the antibody half-life. In a recent efficacy trial in infants, nirsevimab achieved the primary endpoint of reduction of medically attended LRTIs and the secondary endpoint of reduction of hospitalizations and was granted prime eligibility status by the European Medicines Agency (EMA) and breakthrough status by the US FDA. This monoclonal antibody was 100 times more potent than palivizumab. Thanks to the increased antibody efficacy and the extended half-life via engineering technology, a single dose administration at birth provides protection for the entire RSV first season [ 77 ]. Nirsevimab is currently recommended only in infants [ 78 ].

4.2.2.3 Clesrovimab (MK-1654)

Clesrovimab is a monoclonal antibody similar to nirsevimab, and it targets site IV of the RSV prefusion F protein and the same YTE mutation. Studies in children are ongoing to evaluate whether clesrovimab reduces the incidence of RSV-associated medically attended LTRI from day 1 through day 150 post-dose and to assess its safety profile [ 79 ].

4.2.3 Active Immunization

In the last decade, there have been multiple efforts to develop RSV vaccines, with variable results. Several approaches have been developed, such as live attenuated vaccines (LAVs) for infants, stabilized pre-F subunit vaccines for pregnant women, and subunit, vector-based and nucleic acid vaccines for older adults (Fig. 5 ) [ 80 ].

Picture of the effort to track the development of RSV vaccine and mAb candidates worldwide. (Reproduced from the PATH website at www.path.org , April 2024). mAb monoclonal antibody, RSV respiratory syncytial virus, BCG  Bacillus Calmette-Guérin, hMPV human metapneumovirus, NIAID  National Institute of Allergy and Infectious Diseases, NIH  National Institutes of Health, PIV5 Parainfluenza virus 5, SeV Sendai virus, VLP virus-like particle, VRC Vaccine Research Center

LAVs, attenuated through various techniques to reduce virulence [ 81 ], mimic natural RSV infection and are able to induce both a potent humoral mucosal and cellular immune response. Several LAV candidates have been developed and are currently being tested in phase I or II trials, with promising results. Among the others, MV-012-968 was reported to be safe and able to induce a mucosal IgA response in seropositive patients [ 82 ].

Chimeric live virus vaccines consist of related attenuated viral particles expressing RSV-specific proteins. They are reported to have more effective antigen presentation than vectored vaccines, leading to the activation of an intense specific adaptive immune response with a good safety profile [ 83 , 84 ]. Among the two chimeric vaccines that are being studied, the rBCG-N-hRSV vaccine, an attenuated recombinant BCG (Bacillus Calmette-Guérin) vaccine producing RSV nucleoprotein, was proven to be well tolerated in a phase I trial [ 85 ].

Subunit and inactivated virus vaccine development has been abandoned since a formalin-inactivated RSV vaccine was reported to have enhanced the severity of the RSV disease of the first natural RSV infection subsequent to vaccination in RSV-naive children [ 86 ].

In adults, the Adult Respiratory Syncytial Virus (AReSVi-006) study was the first positive trial with a subunit RSV vaccine. It is an ongoing, randomized, multicentric, placebo-controlled trial evaluating the efficacy of the RSVPreF3 OA vaccine (Arexvy, GSK) in adults aged 60 years old or older. This vaccine includes a stabilized RSV F protein, which stimulates the development of specific neutralizing antibodies, and the AS01E adjuvant system. The primary outcome consisted of evaluating the efficacy of this vaccine in preventing RSV-lower respiratory tract disease (LRTD) in older patients during the first season after vaccination. The definition of RSV-LRTD relied on the presence of at least three LRT symptoms or two LRT symptoms or signs (with at least one sign) for at least 1 day. Approximately 25,000 patients were included in this study and randomized 1:1 to receive either placebo or a single dose of vaccine (treatment arm) before the commencement of the RSV season. This vaccination reduced the number of patients who had an RSV-LRTD, with vaccine efficacy detected: 82.6% (96.95% confidence interval [CI] 57.9–94.1) for a median follow-up of 6.7 months (Fig. 6 ). A similar result was achieved in terms of severe RSV-LRTD, with a vaccine efficacy of 94.1% (95% CI 62.4–99.9). The numbers of patients who reported at least one acute respiratory infection (ARI) due to RSV, defined as at least one systemic plus one respiratory sign or symptom or no less than two respiratory signs or symptoms for at least 1 day, were 95 and 27 in the two groups, respectively (vaccine efficacy of 71.7% [95% CI 56.2–82.3]). An equivalent efficacy was reported according to viral subtype (A or B), and it remained high in the two major age groups (60–69 and 70–79) and in frail adults. The responses were specifically evaluated in subgroups according to the presence of specific comorbidities known to be associated with a higher risk of severe disease (described as “conditions of interest” [COI]), such as cardiopulmonary, endocrine, and metabolic comorbidities, where vaccine efficacy was similarly obtained. In addition, the investigational vaccine had a good safety profile [ 87 ].

RSVPreF3 OA vaccine efficacy in reducing incidence of RSV-LRTD and acute respiratory infections. (Reproduced with permission from [ 87 ]). LRTD lower respiratory tract disease, RSV respiratory syncytial virus

For the second season, the initial cohort of patients was divided into three subgroups (placebo, annual vaccination, and single dose) evaluating the vaccine efficacies over two seasons of annual revaccination and single dose. The annual revaccination group showed a vaccine efficacy over two seasons of 67.1% (97.5% CI 48.1–80.0), similar to that of the single dose of vaccine (67.2%, 97.5% CI 48.2–80.0). A sustained vaccine efficacy over two seasons was also reported against RSV-ARI, severe RSV-LRTD, and RSV-LRTD in the groups 60–69 years old and 70–79 years old, patients with at least one COI, and in the prefrail subgroup [ 88 ].

The preventive efficacy on RSV-LRTD and ARI was elevated in patients with at least one COI (94.6% and 81.0%, respectively), at least one cardiopulmonary comorbidity (92.1% and 88.1%, respectively), at least one endocrine/metabolic comorbidity (100% and 79.4%, respectively), and at least two COI (92.0% and 88.0%, respectively). Similarly, the antibody responses to the vaccine were not influenced by the presence of at least one COI [ 89 ].

The RSV Vaccine Efficacy Study in Older Adults Immunized against RSV Disease (RENOIR) trial was a randomized 1:1, multicentre, placebo-control, phase III study evaluating a bivalent vaccine containing an RSV prefusion F protein (RSVpreF vaccine [Abrysvo, Pfizer]) from the two major viral subgroups (RSV-A and B) in older adults 60 years old or older. This formulation did not include an adjuvant system. At the time of this publication, this study was ongoing [ 90 ]. The two primary outcomes of the prespecified interim analysis were the evaluation of the efficacy of the investigational vaccine in the prevention of RSV-LRTD with either two or three symptoms or signs with a duration of at least 24 h in older patients with an RSV infection confirmed by an RT-PCR assay or equivalent test. Approximately 34,000 patients were randomized to receive either the RSVpreF vaccine (treatment arm) or placebo before the beginning of the RSV season, and the mean follow-up was 7 months. The reported RSV-LRTDs with at least two signs/symptoms were 1.19 per 1000 person-years of follow-up in the treatment arm and 3.58 per 1000 person-years of follow-up in the placebo arm (the vaccine efficacy was 66.7%, 96.66% CI 28.8–85.8). RSV-LRTDs with at least three signs/symptoms were 0.22 per 1000 person-years of follow-up in the treatment group and 1.52 per 1000 person-years of follow-up in the other one (the vaccine efficacy was 85.7%, 96.66% CI 32.0–98.7). In addition, the vaccine efficacy did not significantly differ according to viral subtype (A or B), age group (60–69, 70–79, or ≥ 80), and presence of high-risk conditions for adverse outcomes. The cases of RSV-ARI with at least one sign or symptom and a confirmed infection (RT-PCR assay) were 2.38 per 1000 person-years and 6.30 per 1000 person-years in the two study arms, respectively (vaccine efficacy was 62.1%, 95% CI 37.1–77.9). Interestingly, the vaccine efficacy increased with increasing severity of RSV-LRTD, in concordance with the available evidence for other vaccines (e.g. SARS-CoV-2 or influenza virus) [ 90 , 91 , 92 , 93 ].

Of note, the efficacy of the RSVpreF vaccine evaluated in the RENOIR study (adults) was tested in pregnancy for the reduction of RSV-LRTD in infants in the Maternal Immunization Study for Safety and Efficacy (MATISSE) study. The trial showed a significant reduction in medical attended severe RSV-LRTD within 90 and 180 days after delivery and no significant difference for the total cases of RSV-LRTD analysis [ 94 ].

mRNA vaccines consist of messenger RNA coding for specific viral antigens that are able to induce a specific immune response (this vaccination platform was used with COVID-19). The mRNA-1345 vaccine (Moderna) consists of an mRNA encoding a stabilized RSV pre-F protein and a lipid formulation that is able to induce and augment the humoral and cellular immune response to this protein. The ConquerRSV study was a randomized 1:1, multicentre, placebo-controlled, phase III trial evaluating the mRNA-1345 vaccine in a population of approximately 37,000 adults of at least 60 years of age. The two primary outcomes were the prevention of RSV-LRTD with at least two or three symptoms. An interim analysis showed a vaccine efficacy of 83.7% (95.88% CI 66.0–92.2%, p  < 0.0001) in reducing RSV-LRTD defined as at least two signs or symptoms, with 55 and nine cases reported in the placebo arm and vaccine arm, respectively. In addition, RSV-LRTDs with at least three signs or symptoms were reduced from 17 in the placebo arm to three in the vaccine arm, corresponding to a vaccine efficacy of 82.4% (96.36% CI 34.8–95.3%, p  = 0.0078). The investigational vaccine was reported to have a good safety profile and was well tolerated [ 95 ]. The company announced that marketing authorization applications for this investigational vaccine had been submitted to EMA, Swissmedic, and the Therapeutic Goods Administration (TGA) in Australia, along with a rolling submission of a Biologics License Application to the FDA [ 96 ].

Other different vaccine strategies of RSV vaccination already tested and/or currently in development for adults have been recently reviewed in detail [ 62 ]. Here, we summarized only some of the relevant data.

The particle-based vaccines are based on the presentation of multiple antigens via assembled particles inducing a highly effective immune response. These investigational vaccines are currently in early development but with promising results. Icosavax’s IVX-121 consists of a synthetic virus-like particle that delivers multiple copies of stabilized trimeric pre-F proteins and was reported to induce a persistent humoral response at 12 months after the first administration in the interim analysis of the phase Ib extension trial [ 97 ].

The IVX-A12, a combination of the RSV vaccine IVX-121 and the human metapneumovirus (hMPV) vaccine IVX-241, is currently being evaluated in adults in an ongoing phase II clinical study. [ 98 ]

Recombinant vector vaccines consist of modified replication-defective viruses that contain RSV genes codifying for specific antigens stimulating a specific cellular and antibody response. In this field, the MVA-BN-RSV vaccine (Modified vaccinia Ankara-Bavarian Nordic) consists of a poxvirus acting as a vector to express RSV intracellular proteins, such as N and M2, and surface proteins F and G [ 99 ]. MVA-BN-RSV vaccination was associated with a depletion of viral load, a 79% reduction in RSV disease, and a high title humoral response lasting at least 6 months after administration [ 100 , 101 ]. The phase III VANIR study evaluated the efficacy of this vaccine in more than 20,000 participants aged over 60 years. A recent press release reported the preliminary results with a 59% vaccine efficacy in the prevention of LRTD with at least two symptoms. A 42.9% efficacy was reported in the prevention of LRTD with at least three symptoms, which failed to meet one of the co-primary outcomes of the trial, resulting in the discontinuation of Bavarian Nordic’s RSV vaccine development programme [ 102 ].

The Ad26-RSV-pre-F vaccine (Janssen) consists of an adenoviral vector that leads to the expression of the RSV pre-F protein in combination with a recombinant pre-F protein. Ad26-RSV-pre-F was evaluated in the CYPRESS study, a phase IIb, proof-of-concept trial. The primary endpoint was the first occurrence of RSV-LRTD, showing an efficacy of 80% for the most severe disease, defined as three or more LRTD symptoms (94.2% CI 52.2–92.9, p  < 0.001) and 69.8% for all RSV-ARIs (94.2% CI 43.7–84.7, p  < 0.001). The vaccine reduced the severity of symptoms with a faster recovery compared to placebo [ 103 ]. The EVERGREEN study, a phase III trial evaluating this vaccine in older adults, was finally discontinued following a company’s assessment of the RSV vaccine landscape [ 104 , 105 ].

Based on evidence and decisions of regulatory agencies, Arexvy and Abrysvo have been approved and are currently available in the US and Europe. To date, both the FDA and EMA, together with the 2024 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, recommend RSV vaccination in patients older than 60 years old and/or with chronic heart and lung comorbidities. The CDC suggests a single dose of the RSV vaccine for those older than 60 years old, preferably administered a few months before the viral seasonal peak, such as in late summer or early fall. The CDC suggests a shared clinical decision-making (SDM) approach for RSV vaccination. In other words, the decision to proceed with vaccination should be based on an informed patient’s preference reached through an active discussion with the healthcare provider (HCP). This discussion should cover various topics, including available evidence, the patient's health status, risk factors for severe RSV disease, HCP’s suggestions, and the safety profile of the vaccine, among others [ 106 , 107 , 108 , 109 , 110 , 111 ].

In the UK, the Joint Committee on Vaccination and Immunisation (JCVI) suggests RSV vaccination for adults aged at least 75 years old [ 112 ].

In Spain, the Spanish NeumoExperts Prevention Group (NEP) recommends this vaccination among adults over 60 years old, prioritizing those with chronic comorbidities deemed at high risk of severe RSV illness, as well as healthcare workers, who are at elevated risk of both acquiring and transmitting RSV [ 113 ].

Both vaccines should be administered via intramuscular route into the deltoid muscle, and Abrysvo is the only vaccine approved in pregnancy [ 114 , 115 , 116 ].

5 Discussion

Not considered a disease of the youngest anymore, RSV burden remains to date an underestimated cause of morbidity and hospitalization globally in the elderly and immunocompromised population. RSV is an insidious respiratory infection, partly due to nonspecific symptoms, often similar to other viral respiratory tract infections, along with a seasonal pattern of transmission during the wintertime in epidemic outbreaks that recurs annually [ 3 ]. Early diagnosis is challenging, particularly in elderly or fragile patients, where the virus can lead to more severe clinical presentations such as pneumonia, respiratory failure, and Acute Respiratory Distress Syndrome (ARDS). Among the elderly older than 65 years, the European Union is facing 145,000 RSV-associated hospitalizations each year, and the US, 159,000. The mortality rate in elderly hospitalized RSV patients is significant, up to 18% [ 1 , 20 ]. The documented coinfection with other respiratory pathogens, which further complicates the clinical presentation, should not be overlooked. Several studies have demonstrated an increased risk of exacerbation of chronic respiratory diseases (such as asthma and COPD) and an elevated cardiovascular risk in both immunocompetent elderly individuals and those with multiple comorbidities, adding to the overall burden on public health costs. Currently, the most accurate and rapid diagnostic investigation for detecting RSV is RT-PCR amplification on nasal or NP swabs. During the recent COVID-19 pandemic, these tests have become readily available and easy to perform, even by the patients' caregivers themselves. At present, instrumental radiological examinations do not allow the specific detection of pleuro-parenchymal alterations caused by this pathogen. Due to the absence of effective therapies against RSV disease, prophylaxis has rapidly become the most efficient measure to reduce RSV diffusion and clinical impact in the population, especially among the most vulnerable patients such as older adults, polymorbid patients, or those living in nursing facilities. Hygiene measures, such as procedural or structural interventions, have significantly lowered respiratory virus transmission [ 70 ], but active prophylaxis remains essential and should be pursued, targeting those at higher risk of severe disease. Several clinical trials have been conducted and published that show a significant reduction in the incidence of RSV disease, especially in its most severe form. In addition, vaccination was proven to be highly effective regardless of the presence of specific comorbidities and persisted as effective across different seasons [ 87 , 88 , 89 , 90 ]. As a result, regulatory agencies such as the EMA and the FDA have now included RSVPreF3 (Arexvy, GSK) and RSVpreF (Abrysvo, Pfizer) in the suggested vaccinations for individuals over 60 years of age. While Arexvy contains the AS01E adjuvant system, the latter does not contain any adjuvant. Both vaccines protect against the two major RSV subtypes (A and B); Abrysvo is bivalent, containing an RSV prefusion F protein from both RSV-A and B, while Arexvy, even though it is not technically bivalent, demonstrated an optimal efficacy for both subtypes in clinical trials [ 87 , 90 ]. Both Arexvy and Abrysvo can be administered on the same occasion of the influenza vaccination, and national health authorities may approve the simultaneous administration of RSV vaccines with the others [ 111 , 117 ].

In the last decades, significant economic resources have been invested in influenza vaccination. Now it is the time to invest also in RSV vaccination, leading to wider protection against seasonal respiratory viruses in frail and older patients.

6 Conclusions

RSV is a ubiquitous respiratory virus with a seasonal pattern of infection. While RSV represents one of the most common infections during childhood, epidemiological data indicate a substantial impact throughout all ages, with a disproportionately high impact in elderly individuals. RSV carries a serious burden affecting older adults with comorbidities, i.e. the frailest population. No therapeutic option is available for adults. Active immunisation has been recently approved in older adults aged > 60 years old based on the results of multiple phase III studies, such as the RENOIR and AReSVi-006 studies, showing a substantial reduction of RSV-related LTRD and severe LTRD [ 87 , 90 ]. In addition, a single dose of Arexvy has been shown to be as effective as annual revaccination, simplifying the vaccination schedule [ 88 ]. To date, vaccinations represent the best protection from developing severe disease and serious adverse events related to RSV infection, especially for the elderly population with multimorbidities (in particular, cardiopulmonary and metabolic) and immunocompromised individuals.

Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis. J Glob Health. 2015;5(1): 010408.

Article   PubMed   PubMed Central   Google Scholar  

Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H, Investigators R. Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: a systematic review and meta-analysis. J Infect Dis. 2022;226(Suppl 1):S17–21.

Article   PubMed   Google Scholar  

Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;10(366): l5021.

Article   Google Scholar  

Agac A, Kolbe SM, Ludlow M, Osterhaus A, Meineke R, Rimmelzwaan GF. Host responses to respiratory syncytial virus infection. Viruses. 2023;15(10):1999.

Article   CAS   PubMed   PubMed Central   Google Scholar  

Piralla A, Chen Z, Zaraket H. An update on respiratory syncytial virus. BMC Infect Dis. 2023;23(1):734.

Chuang YC, Lin KP, Wang LA, Yeh TK, Liu PY. The impact of the COVID-19 pandemic on respiratory syncytial virus infection: a narrative review. Infect Drug Resist. 2023;16:661–75.

Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–64.

Nichols WG, Gooley T, Boeckh M. Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. Biol Blood Marrow Transplant. 2001;7(Suppl):11S-S15.

Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M. Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica. 2009;94(8):1101–8.

Savic M, Penders Y, Shi T, Branche A, Pircon JY. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2023;17(1): e13031.

Article   CAS   PubMed   Google Scholar  

Childs A, Zullo AR, Joyce NR, McConeghy KW, van Aalst R, Moyo P, et al. The burden of respiratory infections among older adults in long-term care: a systematic review. BMC Geriatr. 2019;19(1):210.

Vikerfors T, Grandien M, Olcen P. Respiratory syncytial virus infections in adults. Am Rev Respir Dis. 1987;136(3):561–4.

Thompson WW, Weintraub E, Dhankhar P, Cheng PY, Brammer L, Meltzer MI, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses. 2009;3(1):37–49.

Conrad A, Valour F, Vanhems P. Burden of influenza in the elderly: a narrative review. Curr Opin Infect Dis. 2023;36(4):296–302.

World Health Organization. Influenza (Seasonal). [cited 2024 8 April]. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) .

Falsey AR, Walsh EE, Esser MT, Shoemaker K, Yu L, Griffin MP. Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure. J Med Virol. 2019;91(1):65–71.

Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling AM, Boas H, et al. Estimation of the number of respiratory syncytial virus-associated hospitalizations in adults in the European Union. J Infect Dis. 2023;228(11):1539–48.

McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac300.

Nguyen-Van-Tam JS, O’Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev. 2022;31(166): 220105.

Kwon YS, Park SH, Kim MA, Kim HJ, Park JS, Lee MY, et al. Risk of mortality associated with respiratory syncytial virus and influenza infection in adults. BMC Infect Dis. 2017;17(1):785.

Ramaswamy M, Groskreutz DJ, Look DC. Recognizing the importance of respiratory syncytial virus in chronic obstructive pulmonary disease. COPD. 2009;6(1):64–75.

Urbani F, Cometa M, Martelli C, Santoli F, Rana R, Ursitti A, et al. Update on virus-induced asthma exacerbations. Expert Rev Clin Immunol. 2023;19(10):1259–72.

Bergeron HC, Tripp RA. Immunopathology of RSV: an updated review. Viruses. 2021;13(12):2478.

Johnson PR, Spriggs MK, Olmsted RA, Collins PL. The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A. 1987;84(16):5625–9.

Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev. 2014;35(12):519–30.

Van Royen T, Rossey I, Sedeyn K, Schepens B, Saelens X. How RSV proteins join forces to overcome the host innate immune response. Viruses. 2022;14(2):419.

Andreano E, Paciello I, Bardelli M, Tavarini S, Sammicheli C, Frigimelica E, et al. The respiratory syncytial virus (RSV) prefusion F-protein functional antibody repertoire in adult healthy donors. EMBO Mol Med. 2021;13(6): e14035.

Pera A, Campos C, Lopez N, Hassouneh F, Alonso C, Tarazona R, et al. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas. 2015;82(1):50–5.

Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25.

Nunez IA, Carlock MA, Allen JD, Owino SO, Moehling KK, Nowalk P, et al. Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS ONE. 2017;12(11): e0185666.

Falsey AR, Formica MA, Hennessey PA, Criddle MM, Sullender WM, Walsh EE. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(6):639–43.

Kaler J, Hussain A, Patel K, Hernandez T, Ray S. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023;15(3): e36342.

PubMed   PubMed Central   Google Scholar  

Lee N, Lui GC, Wong KT, Li TC, Tse EC, Chan JY, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57(8):1069–77.

Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261–9.

Kim D, Quinn J, Pinsky B, Shah NH, Brown I. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020;323(20):2085–6.

Loubet P, Lenzi N, Valette M, Foulongne V, Krivine A, Houhou N, et al. Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. Clin Microbiol Infect. 2017;23(4):253–9.

Hart RJ. An outbreak of respiratory syncytial virus infection in an old people’s home. J Infect. 1984;8(3):259–61.

Belongia EA, King JP, Kieke BA, Pluta J, Al-Hilli A, Meece JK, et al. Clinical features, severity, and incidence of RSV illness during 12 consecutive seasons in a community cohort of adults >/=60 years old. Open Forum Infect Dis. 2018;5(12):ofy316.

Dulek DE, Peebles RS Jr. Viruses and asthma. Biochim Biophys Acta. 2011;1810(11):1080–90.

Kusel MM, de Klerk NH, Kebadze T, Vohma V, Holt PG, Johnston SL, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007;119(5):1105–10.

Wu P, Hartert TV. Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther. 2011;9(9):731–45.

Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130(1):91-100 e3.

Sim YS, Lee JH, Lee EG, Choi JY, Lee CH, An TJ, et al. COPD exacerbation-related pathogens and previous COPD treatment. J Clin Med. 2022;12(1):111.

Mehta J, Walsh EE, Mahadevia PJ, Falsey AR. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD. 2013;10(3):293–9.

Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr. 1976;89(1):11–5.

Mulpuru S, Andrew MK, Ye L, Hatchette T, LeBlanc J, El-Sherif M, et al. Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease. Influenza Other Respir Viruses. 2022;16(6):1172–82.

Anderson NW, Binnicker MJ, Harris DM, Chirila RM, Brumble L, Mandrekar J, et al. Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review. Diagn Microbiol Infect Dis. 2016;85(3):367–71.

Volling C, Hassan K, Mazzulli T, Green K, Al-Den A, Hunter P, et al. Respiratory syncytial virus infection-associated hospitalization in adults: a retrospective cohort study. BMC Infect Dis. 2014;13(14):665.

Gottlieb J, Torres F, Haddad T, Dhillon G, Dilling DF, Knoop C, et al. A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant. J Heart Lung Transplant. 2023;42(7):908–16.

Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev. 2000;13(3):371–84.

Chartrand C, Tremblay N, Renaud C, Papenburg J. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015;53(12):3738–49.

Popow-Kraupp T, Aberle JH. Diagnosis of respiratory syncytial virus infection. Open Microbiol J. 2011;5:128–34.

Onwuchekwa C, Moreo LM, Menon S, Machado B, Curcio D, Kalina W, et al. Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. J Infect Dis. 2023;228(2):173–84.

Onwuchekwa C, Atwell J, Moreo LM, Menon S, Machado B, Siapka M, et al. Pediatric respiratory syncytial virus diagnostic testing performance: a systematic review and meta-analysis. J Infect Dis. 2023;228(11):1516–27.

Wong SS, Yu JW, Wong KT, Lee N, Lui GC, Chan PK, et al. Initial radiographic features as outcome predictor of adult respiratory syncytial virus respiratory tract infection. AJR Am J Roentgenol. 2014;203(2):280–6.

Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015;373(5):415–27.

Kern S, Uhl M, Berner R, Schwoerer T, Langer M. Respiratory syncytial virus infection of the lower respiratory tract: radiological findings in 108 children. Eur Radiol. 2001;11(12):2581–4.

Kim MC, Kim MY, Lee HJ, Lee SO, Choi SH, Kim YS, et al. CT findings in viral lower respiratory tract infections caused by parainfluenza virus, influenza virus and respiratory syncytial virus. Medicine (Baltimore). 2016;95(26): e4003.

Ricco M, Corrado S, Palmieri S, Marchesi F. Respiratory syncytial virus: a systematic review and meta-analysis of tomographic findings (2000–2022). Children (Basel). 2023;10(7):1169.

Empey KM, Peebles RS Jr, Kolls JK. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis. 2010;50(9):1258–67.

Manti S, Staiano A, Orfeo L, Midulla F, Marseglia GL, Ghizzi C, et al. UPDATE—2022 Italian guidelines on the management of bronchiolitis in infants. Ital J Pediatr. 2023;49(1):19.

Langedijk AC, Bont LJ. Respiratory syncytial virus infection and novel interventions. Nat Rev Microbiol. 2023;21(11):734–49.

Turner TL, Kopp BT, Paul G, Landgrave LC, Hayes D Jr, Thompson R. Respiratory syncytial virus: current and emerging treatment options. Clinicoecon Outcomes Res. 2014;6:217–25.

DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371(8):711–22.

Cockerill GS, Angell RM, Bedernjak A, Chuckowree I, Fraser I, Gascon-Simorte J, et al. Discovery of sisunatovir (RV521), an inhibitor of respiratory syncytial virus fusion. J Med Chem. 2021;64(7):3658–76.

Gao Y, Cao J, Xing P, Altmeyer R, Zhang Y. Evaluation of small molecule combinations against respiratory syncytial virus in vitro. Molecules. 2021;26(9):2607.

Zheng X, Gao L, Wang L, Liang C, Wang B, Liu Y, et al. Discovery of ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor. J Med Chem. 2019;62(13):6003–14.

Huang LM, Schibler A, Huang YC, Tai A, Chi H, Chieng CH, et al. Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: a phase 2 proof-of-concept trial. Influenza Other Respir Viruses. 2023;17(7): e13176.

Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic—United States, 2020–2021. MMWR Morb Mortal Wkly Rep. 2021;70(29):1013–9.

Malara A, Noale M, Trevisan C, Abbatecola AM, Borselli G, Cafariello C, et al. Efficacy of COVID-19 control measures on post-vaccination outbreak in Italian Long Term Care Facilities: implications for policies. Front Public Health. 2023;11:1091974.

Samson L. Prevention of respiratory syncytial virus infection. Paediatr Child Health. 2009;14(8):521–32.

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531–7.

Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis. 2001;184(3):350–4.

Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010;12(1):38–44.

McCoy D, Wong E, Kuyumjian AG, Wynd MA, Sebti R, Munk GB. Treatment of respiratory syncytial virus infection in adult patients with hematologic malignancies based on an institution-specific guideline. Transpl Infect Dis. 2011;13(2):117–21.

Tsitsikas DA, Oakervee H, Cavenagh JD, Gribben J, Agrawal SG, Mattes FM. Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience. Br J Haematol. 2009;146(5):574–6.

Ruckwardt TJ, Morabito KM, Graham BS. Immunological lessons from respiratory syncytial virus vaccine development. Immunity. 2019;51(3):429–42.

Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sanchez PJ, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(34):920–5.

Esposito S, Amirthalingam G, Bassetti M, Blasi F, De Rosa FG, Halasa NB, et al. Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy. Front Immunol. 2023;14:1162342.

Mazur NI, Terstappen J, Baral R, Bardaji A, Beutels P, Buchholz UJ, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023;23(1):e2–21.

Karron RA, Atwell JE, McFarland EJ, Cunningham CK, Muresan P, Perlowski C, et al. Live-attenuated vaccines prevent respiratory syncytial virus-associated illness in young children. Am J Respir Crit Care Med. 2021;203(5):594–603.

Meissa Vaccines I. Meissa vaccines provides a pipeline update on vaccine candidates for COVID-19 and RSV. June 30, 2020. https://www.meissavaccines.com/post/meissa-vaccines-provides-a-pipeline-update-on-vaccine-candidates-for-covid-19-and-rsv Accessed 12 Apr 2022.

Scaggs Huang F, Bernstein DI, Slobod KS, Portner A, Takimoto T, Russell CJ, et al. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Hum Vaccin Immunother. 2021;17(2):554–9.

Wiegand MA, Gori-Savellini G, Gandolfo C, Papa G, Kaufmann C, Felder E, et al. A respiratory syncytial virus vaccine vectored by a stable chimeric and replication-deficient Sendai virus protects mice without inducing enhanced disease. J Virol. 2017;91(10).

Abarca K, Rey-Jurado E, Munoz-Durango N, Vazquez Y, Soto JA, Galvez NMS, et al. Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine. 2020;27: 100517.

Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS. Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine. 2013;31(Suppl 2):B209-15.

Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595–608.

Ison MG, Papi A, Langley JM. Efficacy of one dose of the respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in adults ≥ 60 years of age persists for 2 RSV seasons. Abstract presented at IDWeek; October 11–15, 2023; Boston, MA. https://www.patientcareonline.com/view/idweek-2023-late-breaker-efficacy-of-single-rsvpref3-dose-sustained-over-2-seasons-in-high-risk-older-adults . Accessed 14 Dec 2023.

Feldman RG, Antonelli-Incalzi R, Steenackers K, Lee DG, Papi A, Ison MG, et al. Respiratory syncytial virus prefusion f protein vaccine is efficacious in older adults with underlying medical conditions. Clin Infect Dis. 2023.

Walsh EE, Perez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465–77.

Ferdinands JM, Thompson MG, Blanton L, Spencer S, Grant L, Fry AM. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine. 2021;39(28):3678–95.

Florentino PTV, Millington T, Cerqueira-Silva T, Robertson C, de Araujo OV, Junior JBS, et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study. Lancet Infect Dis. 2022;22(11):1577–86.

He X, Su J, Ma Y, Zhang W, Tang S. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. Front Immunol. 2022;13: 945930.

Kampmann B, Madhi SA, Munjal I, Simoes EAF, Pahud BA, Llapur C, et al. Bivalent prefusion F Vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451–64.

Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, et al. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults. N Engl J Med. 2023;389(24):2233–44.

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345. In Investor Relations—Moderna. 2023. https://investors.modernatx.com/news/news-details/2023/Moderna-Announces-Global-Regulatory-Submissions-For-Its-Respiratory-Syncytial-Virus-RSV-Vaccine-MRNA-1345/default.aspx . Accessed 02 Apr 2024.

Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine Candidate IVX-121 Against RSV. In: Icosavax; 2022. https://ir.icosavax.com/news-releases/news-release-details/icosavax-announces-positive-topline-interim-phase-11b-results/ . Accessed 02 Apr 2024.

Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults. In: Icosavax; 2023. https://ir.icosavax.com/news-releases/news-release-details/icosavax-initiates-phase-2-trial-ivx-a12-against-rsv-and-hmpv/ . Accessed 02 Apr 2024.

Samy N, Reichhardt D, Schmidt D, Chen LM, Silbernagl G, Vidojkovic S, et al. Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: a randomized phase I clinical trial. Vaccine. 2020;38(11):2608–19.

Weidenthaler H, Schultz S, Sanos S, et al. VT&T-77: efficacy, safety and immunogenicity of the recombinant MVA-BN-RSV vaccine against respiratory syncytial virus (RSV) infection in a human challenge trial (HCT) in healthy adult participants. In: RSVVW’21 Abstract Booklet. Virtual: RSVVW’21: 6th ReSViNet Conference: November 10–12, 2021 (abstr VT&T-77).

Jordan E, Kabir G, Schultz S, Silbernagl G, Schmidt D, Jenkins VA, et al. Reduced respiratory syncytial virus load, symptoms, and infections: A human challenge trial of MVA-BN-RSV vaccine. J Infect Dis. 2023;228(8):999–1011.

Bavarian Nordic Provides Update On Rsv Vaccine Program. In: Bavarian Nordic. 2023. https://www.bavarian-nordic.com/Investor/News/News.aspx?News=6808 . Accessed 02 Apr 2024.

Falsey AR, Williams K, Gymnopoulou E, Bart S, Ervin J, Bastian AR, et al. Efficacy and safety of an Ad26.RSV.preF-RSV preF protein vaccine in older adults. N Engl J Med. 2023;388(7):609–20.

ClinicalTrails.gov. Identifier: NCT04908683, a study of an adenovirus serotype 26 pre-fusion conformation-stabilized F protein (Ad26. RSV. pre-F) based respiratory syncytial virus (RSV) vaccine in the prevention of lower respiratory tract disease in adults aged 60 years and O. June 1, 2021. https://clinicaltrials.gov/ct2/show/ NCT04908683. Accessed 14 Dec 2023.

Janssen provides portfolio update. News release. Johnson & Johnson. March 29, 2023. Accessed 14 Dec 2023. https://www.jnj.com/janssen-provides-portfolio-update .

Global Initiative for Chronic Obstructive Lung Disease—GOLD. Global strategy for prevention, diagnosis and management of COPD: 2024 Report. https://goldcopd.org/wp-content/uploads/2023/11/KEY-CHANGES-GOLD-2024.pdf . Accessed 14 Dec 2023.

Pfizer Inc. U.S. FDA Approves ABRYSVOTM, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults. In: Pfizer. 2023. https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention . Accessed 02 Apr 2024.

U.S. Food and Drug Administration. FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. In: U.S. Food and Drug Administration. 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine . Accessed 02 Apr 2024.

GlaxoSmithKline. European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults. In: GlaxoSmithKline. 2023. https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ . Accessed 02 Apr 2024.

Pfizer Inc. European Commission Approves Pfizer’s ABRYSVOTM to Help Protect Infants through Maternal Immunization and Older Adults from RSV. In: Pfizer. 2023. https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-abrysvotm-help-protect . Accessed 02 Apr 2024.

Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793–801.

Joint Committee on Vaccination and Immunisation (JCVI). Respiratory syncytialvirus (RSV) immunisation programme for infants and older adults: JCVI fullstatement. In: Department of Health & Social Care, UK. 2023. https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023#background . Accessed 8 Apr 2024.

Redondo E, Rivero-Calle I, Mascaros E, Ocana D, Jimeno I, Gil A, et al. Respiratory syncytial virus vaccination recommendations for adults aged 60 years and older: The NeumoExperts prevention group position paper. Arch Bronconeumol. 2024;60(3):161–70.

EMA-EPAR. Abrysvo Respiratory syncytial virus vaccine (bivalent, recombinant). 2023.

EMA-EPAR. Arexvy (Recombinant respiratory syncytial virus pre-fusion F pro-tein, adjuvanted with AS01E. 2023.

Centers for Disease Control and Prevention. Healthcare Providers: RSV Vaccination for Pregnant People. In: Centers for Disease Control and Prevention; 2023. https://www.cdc.gov/vaccines/vpd/rsv/hcp/pregnant-people.html . Accessed 02 Apr 2024.

Melgar M. Updated Evidence to Recommendation Framework: respiratory syncytial virus (RSV) in adults. Advisory Committee on Immunization Practices meeting; June 21. Atlanta, GA; 2023.

Download references

Acknowledgements

The authors thank Elisa Veratelli for editorial support. This editorial support was funded by Consorzio Futuro as authorized by the University of Ferrara.

Author information

Authors and affiliations.

Respiratory Unit, Department of Translational Medicine, University of Ferrara Medical School, University of Ferrara, Sant’Anna University Hospital, Via Aldo Moro, 8, 44124, Ferrara, Italy

Franco Alfano, Tommaso Bigoni, Francesco Paolo Caggiano & Alberto Papi

You can also search for this author in PubMed   Google Scholar

Corresponding author

Correspondence to Alberto Papi .

Ethics declarations

Author contributions.

All authors contributed to literature review and data evaluation. AP prepared the first draft of manuscript. All authors critically revised and contributed to the finalization of the manuscript. All authors read and approved the final version of the manuscript.

Open access funding provided by Università degli Studi di Ferrara within the CRUI-CARE Agreement.

Data Availability

Not applicable.

Conflict of Interest

AP received grants for research from Chiesi, Astrazeneca, GSK, and Sanofi; consulting fees or advisory board fees from Chiesi, Astrazeneca, GSK, Mundipharma, Novartis, Edmond, Sanofi, Avillion, IQVIA, Elpen Pharmaceuticals, TEVA, and MSD, and lecture fees form Chiesi, Astrazeneca, GSK, Mundipharma, Sanofi, MSD, Novartis, and Zambon outside the submitted work. FA, TB, and FPC have nothing to disclose.

Ethics Approval

Not applicable

Informed Consent

Rights and permissions.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ .

Reprints and permissions

About this article

Alfano, F., Bigoni, T., Caggiano, F.P. et al. Respiratory Syncytial Virus Infection in Older Adults: An Update. Drugs Aging (2024). https://doi.org/10.1007/s40266-024-01118-9

Download citation

Accepted : 19 April 2024

Published : 07 May 2024

DOI : https://doi.org/10.1007/s40266-024-01118-9

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Find a journal
• Publish with us
• Track your research

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

11 templates

teacher appreciation

mother teresa

18 templates

memorial day

12 templates

summer vacation

25 templates

Protecting Your Computer: Antivirus

Protecting your computer: antivirus presentation, free google slides theme and powerpoint template.

Having the right antivirus installed on your computer is a must. Everyone knows this, yet some people still choose not to install some antivirus software and protect their computers. This is when your antivirus presentation comes into action! Help others choose to protect their computers by informing them on the risks of cyberattacks and viruses they can suffer without the right protection. Capture everyone’s attention with these cute flat illustrations of users, computers and potential viruses. Download this template now and present the importance of antivirus!

Features of this template

• 100% editable and easy to modify
• 36 different slides to impress your audience
• Contains easy-to-edit graphics such as graphs, maps, tables, timelines and mockups
• Includes 500+ icons and Flaticon’s extension for customizing your slides
• Designed to be used in Google Slides and Microsoft PowerPoint
• 16:9 widescreen format suitable for all types of screens
• Includes information about fonts, colors, and credits of the resources used

How can I use the template?

Am I free to use the templates?

How to attribute?

Attribution required If you are a free user, you must attribute Slidesgo by keeping the slide where the credits appear. How to attribute?

Related posts on our blog.

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides

Related presentations.

Premium template

Unlock this template and gain unlimited access